Review Article| Volume 50, ISSUE 1, P133-143, February 2023

Biomarkers in Testicular Cancer

Classic Tumor Markers and Beyond
  • Jillian Egan
    Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Search for articles by this author
  • Keyan Salari
    Corresponding author: Keyan Salari, MD, PhD, Department of Urology, Massachusetts General Hospital, 55 Fruit St, GRB-1106H, Boston, MA, 02114.
    Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Center for Genitourinary Cancers, Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA USA
    Search for articles by this author


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Urologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors. Available at:

        • Nigam M.
        • Aschebrook-Kilfoy B.
        • Shikanov S.
        • et al.
        Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009.
        World J Urol. 2015; 33: 623-631
        • Ghazarian A.A.
        • McGlynn K.A.
        Increasing incidence of testicular germ cell tumors among racial/ethnic minorities in the United States.
        Cancer Epidemiol Biomarkers Prev. 2020; 29: 1237-1245
        • Stephenson A.
        • Eggener S.E.
        • Bass E.B.
        • et al.
        Diagnosis and treatment of early stage testicular cancer: AUA guideline.
        J Urol. 2019; 202: 272-281
        • Honecker F.
        • Aparicio J.
        • Berney D.
        • et al.
        ESMO consensus conference on testicular germ cell cancer: Diagnosis, treatment and follow-up.
        Ann Oncol. 2018; 29: 1658-1686
        • Mead G.M.
        International germ cell consensus classification: a prognostic factor- based staging system for metastatic germ cell cancers.
        J Clin Oncol. 1997; 15: 594-603
        • Gillessen S.
        • Sauvé N.
        • Collette L.
        • et al.
        Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): Results from the IGCCCG update consortium.
        J Clin Oncol. 2021; 39: 1563-1574
        • Beyer J.
        • Collette L.
        • Sauvé N.
        • et al.
        Survival and new prognosticators in metastatic seminoma: Results from the IGCCCG-update consortium.
        J Clin Oncol. 2021; 39: 1553-1562
        • Lobo J.
        • Leão R.
        • Jerónimo C.
        • et al.
        Liquid biopsies in the clinical management of germ cell tumor patients: State-of-the-art and future directions.
        Int J Mol Sci. 2021; 22: 1-22
        • Wein Alan J.
        • Kavoussi Louis R.
        • Partin Alan W.
        • et al.
        Campbell-walsh urology.
        10th ed. Elsevier Saunders, Philadelphia, PA2016
        • Javadpour N.
        The role of biologic tumor markers in testicular cancer.
        Cancer. 1980; 45: 1755-1761
        • Lange P.H.
        • Winfield H.N.
        Biological markers in urologic cancer.
        Cancer. 1987; 60: 464-472
        • Milose J.C.
        • Filson C.P.
        • Weizer A.Z.
        • et al.
        Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance.
        Open Access J Urol. 2011; 4: 1-8
        • Talerman A.
        • Haije W.G.
        • Baggerman L.
        Alpha-1 antitrypsin (AAT) and alphafoetoprotein (AFP) in sera of patients with germ-cell neoplasms: Value as tumour markers in patients with endodermal sinus tumour (yolk sac tumour).
        Int J Cancer. 1977; 19: 741-746
        • Syring I.
        • Bartels J.
        • Holdenrieder S.
        • et al.
        Circulating Serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as Biomarkers in Patients with Testicular Germ Cell Cancer.
        J Urol. 2015; 193: 331-337
        • Wymer K.M.
        • Daneshmand S.
        • Pierorazio P.M.
        • et al.
        Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment.
        Ann Oncol. 2017; 28: 899-902
        • Dieckmann K.P.
        • Radtke A.
        • Spiekermann M.
        • et al.
        Serum Levels of MicroRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours.
        Eur Urol. 2017; 71: 213-220
        • Stenman U.H.
        • Alfthan H.
        • Hotakainen K.
        Human chorionic gonadotropin in cancer.
        Clin Biochem. 2004; 37: 549-561
        • Germa J.R.
        • Arcusa A.
        • Casamitjana R.
        False elevations of human chorionic gonadotropin associated to latrogenic hypogonadism in gonadal germ cell tumors.
        Cancer. 1987; 60: 2489-2493
        • Catalona W.J.
        • Vaitukaitis J.L.
        • Fair W.R.
        Falsely positive specific human chorionic gonadotropin assays in patients with testicular tumors: Conversion to negative with testosterone administration.
        J Urol. 1979; 122: 126-128
        • Garnick M.B.
        Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer.
        N Engl J Med. 1980; 303: 1177
        • Harclerode J.
        Endocrine effects of marijuana in the male: preclinical studies.
        NIDA Res Monogr. 1984; 44: 46-64
        • Braunstein G.D.
        • Thompson R.
        • Gross S.
        • et al.
        Marijuana use does not spuriously elevate serum human chorionic gonadotropin levels.
        Urology. 1985; 25: 605-606
        • Von Eyben F.E.
        • Blaabjerg O.
        • Petersen P.H.
        • et al.
        Serum lactate dehydrogenase isoenzyme 1 as a marker of testicular germ cell tumor.
        J Urol. 1988; 140: 986-989
        • Toner G.C.
        • Geller N.L.
        • Tan C.
        • et al.
        Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
        Cancer Res. 1990; 50: 5904-5910
        • Soares D.G.
        • Millot F.
        • Lacroix I.
        • et al.
        Heterophile Antibody Interference led to Unneeded Chemotherapy in a Testicular Cancer Patient.
        Urol Case Reports. 2016; 9: 1-3
        • Bolstad N.
        • Warren D.J.
        • Nustad K.
        Heterophilic antibody interference in immunometric assays.
        Best Pract Res Clin Endocrinol Metab. 2013; 27: 647-661
        • Murray M.J.
        • Halsall D.J.
        • Hook C.E.
        • et al.
        Identification of microRNAs From the miR-371∼373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors.
        Am J Clin Pathol. 2011; 135: 119-125
        • Nappi L.
        • Thi M.
        • Lum A.
        • et al.
        Developing a highly specific biomarker for germ cell malignancies: Plasma MiR371 expression across the germ cell malignancy spectrum.
        J Clin Oncol. 2019; 37: 3090-3098
        • Voorhoeve P.M.
        • le Sage C.
        • Schrier M.
        • et al.
        A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.
        Adv Exp Med Biol. 2007; 604: 17-46
        • Lafin J.T.
        • Singla N.
        • Woldu S.L.
        • et al.
        Serum MicroRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.
        Eur Urol. 2020; 77: 290-292
        • Leão R.
        • van Agthoven T.
        • Figueiredo A.
        • et al.
        Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor.
        J Urol. 2018; 200: 126-135
        • Mego M.
        • van Agthoven T.
        • Gronesova P.
        • et al.
        Clinical utility of plasma miR-371a-3p in germ cell tumors.
        J Cell Mol Med. 2019; 23: 1128-1136
        • Abol-Enein H.
        • Ghoneim M.A.
        Functional results of orthotopic ileal neobladder with serous-lined extramural ureteral reimplantation: experience with 450 patients.
        J Urol. 2001; 165: 1427-1432
        • van Agthoven T.
        • Looijenga L.H.J.
        Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test).
        Oncotarget. 2017; 8: 58037-58049
        • Dieckmann K.P.
        • Spiekermann M.
        • Balks T.
        • et al.
        MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours.
        Br J Cancer. 2012; 107: 1754-1760
        • Dieckmann K.P.
        • Radtke A.
        • Geczi L.
        • et al.
        Serum Levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: Results of a prospective multicentric study.
        J Clin Oncol. 2019; 37: 1412-1423
        • Shen H.
        • Shih J.
        • Hollern D.P.
        • et al.
        Integrated molecular characterization of testicular germ cell tumors.
        Cell Rep. 2018; 23: 3392-3406
        • Lobo J.
        • van Zogchel L.M.J.
        • Nuru M.G.
        • et al.
        Combining hypermethylated rassf1a detection using ddpcr with mir-371a-3p testing: an improved panel of liquid biopsy biomarkers for testicular germ cell tumor patients.
        Cancers (Basel). 2021; 13: 1-15
        • Chovanec M.
        • Albany C.
        • Mego M.
        • et al.
        Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice.
        Front Oncol. 2018; 8: 1-7
        • Nappi L.
        • Thi M.
        • Adra N.
        • et al.
        Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors.
        Eur Urol. 2021; 79: 16-19
        • Belge G.
        • Grobelny F.
        • Radtke A.
        • et al.
        Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin.
        J Cancer Res Clin Oncol. 2021; 147: 435-443
        • Agathanggelou A.
        • Cooper W.N.
        • Latif F.
        Role of the Ras-association domain family 1 tumor suppressor gene in human cancers.
        Cancer Res. 2005; 65: 3497-3508
      2. A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors. Available at:

      3. NCT04435756. A Study of miRNA 371 in Patients With Germ Cell Tumors.
        (Available at:)
        • Ellinger J.
        • Wittkamp V.
        • Albers P.
        • et al.
        Cell-Free Circulating DNA: diagnostic value in patients with testicular germ cell cancer.
        J Urol. 2009; 181: 363-371
        • Afrifa J.
        • Zhao T.
        • Yu J.
        Circulating mitochondria DNA, a non-invasive cancer diagnostic biomarker candidate.
        Mitochondrion. 2019; 47: 238-243
        • Ellinger J.
        • Albers P.
        • Müller S.C.
        • et al.
        Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker.
        BJU Int. 2009; 104: 48-52
        • Yang C.
        • Xia B.R.
        • Jin W.L.
        • et al.
        Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model.
        Cancer Cell Int. 2019; 19: 1-13
        • Hildebrandt M.
        • Bläser F.
        • Beyer J.
        • et al.
        Detection of tumor cells in peripheral blood samples from patients with germ cell tumors using immunocytochemical and reverse transcriptase-polymerase chain reaction techniques.
        Bone Marrow Transpl. 1998; 22: 771-775
        • Yuasa T.
        • Yoshiki T.
        • Tanaka T.
        • et al.
        Detection of circulating testicular cancer cells in peripheral blood.
        Cancer Lett. 1999; 143: 57-62
        • Hautkappe A.L.
        • Lu M.
        • Mueller H.
        • et al.
        Detection of germ-cell tumor cells in the peripheral blood by nested reverse transcription-polymerase chain reaction for alpha-fetoprotein-messenger RNA and beta human chorionic gonadotropin-messenger RNA.
        Cancer Res. 2000; 60: 3170-3174
        • Nastały P.
        • Honecker F.
        • Pantel K.
        • et al.
        Detection of circulating tumor cells (CTCs) in patients with testicular germ cell tumors.
        Methods Mol Biol. 2021; 2195: 245-261